Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1064 clinical trials
Featured trial
RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.

RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.

  • 207 views
  • 08 Nov, 2020
  • 1 location
Featured trial
ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

  • 258 views
  • 08 Nov, 2020
  • 1 location
Featured trial
Phase 1 study of BAY1905254 - An early clinical research study to evaluate a new drug called Bapotulimab (BAY1905254) in the expansion cohort in combination with Pembolizumab in Head and Neck cancer that has returned or is discovered to be metastatic and is expressing PDL1.

the recurrent or metastatic Head and Neck Cancer.

primary tumor
pembrolizumab
metastatic head and neck cancer
carcinoma
metastatic head and neck squamous cell carcinoma
  • 0 views
  • 14 Sep, 2021
  • 8 locations
Featured trial
RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

of the Head and Neck

  • 492 views
  • 08 Nov, 2020
  • 1 location
Featured trial
RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

  • 766 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

cancer
advanced cancer
  • 226 views
  • 10 May, 2022
  • 4 locations
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy (MINER)

enrolled in the trial: Non-Small Cell Lung Cancer (NSCLC), Head and neck cancer, Melanoma, Bladder cancer, Other tumor types when Immuno-Oncology agent

  • 12 views
  • 26 Apr, 2022
  • 2 locations
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Background: Locally advanced head and neck cancer (HNC) is a challenge as, in spite of initial good control with chemoradiation, the majority of patients fails systemically. In the last 2 years

  • 55 views
  • 15 Feb, 2022
  • 1 location
Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer

Oral mucositis (OM) is an acute side effect of radiotherapy for head and neck cancer (HNC). OM associated pain affects oral functions and nutrition of the patient that may result in

  • 2 views
  • 21 Feb, 2022
  • 12 locations
Carbon Ion Re-Radiotherapy in Patients With Recurrent or Progressive Locally Advanced Head-and-Neck Cancer

-irradiation in patients with recurrent or progressive locally advanced head-and-neck cancer will be assessed regarding toxicity/ safety, local progression-free survival, overall survival and quality-of-life

  • 2 views
  • 18 Oct, 2021
  • 1 location